Novartis AG - ADR

This committee's expertise and official 'revenue estimates' are crucial for all tax legislation. Given that tax policy (handled by the Finance Committee) has a 'high' impact on Novartis's corporate valuations and international structure, the body directly influencing and validating tax bills is equally highly relevant.

This is a highly influential committee controlling taxation, trade, and entitlement spending. It directly impacts Novartis's profitability through tax policy, its global operations through trade policy, and its revenues through Medicare and Medicaid drug pricing and reimbursement.

This committee directly allocates discretionary federal spending. Its subcommittees determine the specific funding levels for crucial entities like the FDA, NIH, and major healthcare programs (e.g., Medicare, Medicaid) that purchase or reimburse for Novartis's products.

This committee has direct oversight of the FDA, which regulates drug approval, manufacturing, and marketing – core functions for Novartis. It also oversees the NIH, impacting biomedical research funding, and labor laws, affecting operational costs.

This committee's oversight of antitrust laws directly impacts potential mergers and acquisitions for Novartis, and its jurisdiction over intellectual property (patents) is foundational to protecting the R&D and market exclusivity of its innovative medicines segment.